SAM
IRMD icon

Silphium Asset Management’s iRadimed IRMD Stock Holding History

Silphium Asset Management’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,000
Closed -$223K – 70
2018
Q3 		$223K Buy
+6,000
New +$162K 0.06% 106

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
NA
Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Silphium Asset Management's IRMD Position: Q4 2018 in Review

Silphium Asset Management sold out of iRadimed (IRMD) in Q4 2018, closing a stake of 6,000 shares — an estimated $223K sold.

Silphium Asset Management first reported a position in IRMD in Q3 2018 and held it in 1 quarter. The position peaked at $223K in Q3 2018. 67 funds tracked by Wall St. Rank hold IRMD as of Q4 2018.

  • Silphium Asset Management reported no remaining iRadimed position as of Q4 2018 after selling out during the quarter.
  • Silphium Asset Management sold 6,000 iRadimed shares in Q4 2018, an estimated $223K.
  • Silphium Asset Management first reported a position in iRadimed in Q3 2018 and held it in 1 quarter.
  • Silphium Asset Management's iRadimed position peaked at $223K in Q3 2018.
  • 67 funds tracked by Wall St. Rank held iRadimed as of Q4 2018.

Based on Silphium Asset Management's 13F filing for Q4 2018, filed 30 Jan 2025.